TB-500 side effects and safety

The TB-500 side effects profile is among the mildest in the peptide therapy category, anchored by a completed Phase 1 human clinical trial confirming tolerability. Here is what the published safety data actually shows, what the reported negative side effects are, the cancer concern that shaped early regulatory attention, the current WADA prohibition, and the legal status of TB-500 in 2026 following FDA Category 2 removal.

Phase 1 human safety data

The most important piece of TB-500 side effects in humans evidence is the completed Phase 1 clinical trial (PMID 34346165). This trial evaluated the safety, tolerability, and pharmacokinetics of synthetic Thymosin Beta-4 administered to human subjects. The key findings: TB-500 was well-tolerated across the dose ranges tested, no dose-limiting toxicities were identified, no serious adverse events were attributed to the study drug, and pharmacokinetic parameters were consistent with subcutaneous peptide administration. This trial was designed as a safety study — it did not evaluate efficacy — but it established that TB-500 does not produce acute organ toxicity, hematological derangement, or cardiovascular adverse effects at the doses used.

Reported TB-500 side effects

From the Phase 1 trial, clinical case reports, veterinary use data, and community reports, the commonly described TB-500 negative side effects include:

The temporary increase in inflammation at injury sites — sometimes called a “healing flare” — deserves specific mention. Because TB-500 promotes cell migration to injury sites, the initial phase of treatment can produce increased inflammation at pre-existing injury sites as repair cells accumulate. This is generally considered a positive signal (the healing response is activating) rather than a side effect per se, and it typically resolves within the first week of the protocol.

The cancer question

The most persistent safety concern about TB-500 involves cancer. Thymosin Beta-4 is overexpressed in certain tumor cell lines, which led to early speculation that exogenous Tβ4 administration might promote tumor growth or metastasis. This concern has been studied extensively. The current scientific consensus, reflected in multiple review articles, is that Tβ4 overexpression in tumors is a consequence of the cancer phenotype rather than a cause. Cancer cells are highly migratory (which is what makes them metastatic), and because Tβ4 is the primary actin-sequestering protein involved in cell migration, aggressive cancer cells naturally upregulate Tβ4 expression as part of their migratory machinery. No published study has demonstrated that administering exogenous TB-500 to healthy organisms initiates cancer or accelerates existing tumor growth. However, this remains a theoretical concern — people with active malignancies should discuss TB-500 with their oncologist before use.

Is TB-500 legal?

The legal status of TB-500 depends on context. For research purposes, TB-500 is legally sold and purchased in most jurisdictions as a research chemical. For clinical use in the United States: TB-500 was placed on the FDA Category 2 bulk drug substances list in 2023, which restricted compounding pharmacies from preparing TB-500 prescriptions. On April 15, 2026, the FDA removed TB-500 from Category 2, effective April 22, 2026. This removed the enforcement basis for the compounding restriction but did not affirmatively authorize compounding — TB-500 has not yet been placed on the FDA Category 1 list that formally authorizes 503A and 503B compounding. The PCAC (Pharmacy Compounding Advisory Committee) meeting scheduled for July 23–24, 2026 will review TB-500 and other peptides for Category 1 inclusion.

TB-500 and WADA

TB-500 is banned in competition by the World Anti-Doping Agency (WADA) under the S2 category: Peptide Hormones, Growth Factors, Related Substances, and Mimetics. This prohibition applies to all athletes subject to WADA-code testing, including Olympic, NCAA, and professional athletes in WADA-compliant leagues. TB-500 WADA detection is possible through standard anti-doping urine testing — the peptide and its metabolites are detectable for a window that varies by dose and individual metabolism. Athletes who are asked “is TB-500 banned?” should understand that it is unconditionally prohibited both in-competition and out-of-competition under current WADA rules. Thymosin Beta-4 WADA status is identical — the parent protein is also prohibited under S2.

TB-500 side effects: what the community reports

The TB-500 side effects Reddit community discussion largely mirrors the clinical safety profile: injection site reactions, occasional headache, and transient fatigue are the most commonly reported experiences. Serious adverse events are extremely rare in community reports. The most frequently discussed concern on peptide forums is the cancer question addressed above. Some users report a temporary “flu-like” feeling in the first 1–2 days of a new TB-500 protocol, which is consistent with the immune-modulatory effects of Thymosin Beta-4 family peptides and typically resolves without intervention.